SCHEMBL2474768

SCHEMBL2474768

CN(C)CCCC(NC(=O)Nc1ccc([N+](=O)[O-])cc1)c1ccc(C(=O)Nc2ccccc2NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 10/20 0.44
HDAC1 Q13547 2/20 0.42
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
HDAC6 Q9UBN7 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480439 0.90 UTS2R (0.47) UTS2RHDAC1ROCK2ROCK1
SCHEMBL2474055 0.89 UTS2R (0.47) UTS2RHDAC1HTTMAPTNPC1
SCHEMBL2478032 0.88 UTS2R (0.41) UTS2RHDAC1HTTMAPTKMT2A
SCHEMBL3831084 0.88 HDAC1 (0.42) HDAC1POLBHTTMAPTNPC1
SCHEMBL2475578 0.87 UTS2R (0.47) UTS2RHDAC1NPC1RAB9AKMT2A
SCHEMBL2477098 0.86 UTS2R (0.46) UTS2RHDAC1MAPTROCK2ROCK1
SCHEMBL3829358 0.86 HDAC1 (0.58) UTS2RHDAC1POLBHTTABCG2
SCHEMBL3832774 0.85 UTS2R (0.53) UTS2RROCK2ROCK1
SCHEMBL2479563 0.85 UTS2R (0.44) UTS2RHDAC1ROCK2ROCK1
SCHEMBL4390128 0.85 LTA4H (0.47) UTS2RHDAC1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 UTS2R 11/4885HDAC1 200/4885POLB 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.